- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06323252
A Study on the Effects of Mastiha Oil in Adults With Hypertriglyceridemia
Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of Mastiha. Its composition is high in bioactive ingredients (such as terpenic acids and polyphenols) which have proven anti-inflammatory, antioxidant, cardioprotective, chemoprotective and antimicrobial properties. The aim of this study is to determine the effect of Mastiha oil in adults with Hypetriglyceridemia. 100 participants will be allocated to two groups, (50 in intervention group and 50 in control group). Mastiha oil will be provided in the form of soft gel capsules to the intervention group, whereas the control group will not consume the capsules. Both groups will receive standard nutritional counselling. The intervention will last 3 months.
The effects of the intervention will be evaluated via clinical and laboratory markers.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andriana C Kaliora, Ass. Professor
- Phone Number: 30 +30 2109549226
- Email: akaliora@hua.gr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 30 years < Age < 75 years Hypetriglyceridemia A stable weight for ≥ 3 months pre-intervention An unchanged treatment regimen for ≥ 6 months pre-intervention
Exclusion Criteria:
Hepatotoxic Medication Untreated Diabetes Mellitus Dysthyroidism, hypopituitarism, Cushing syndrome / disease Pregnancy, lactation Psychiatric or mental disorder Any use of antioxidant-phytochemical rich supplement, vitamin D supplement, anti-, pre- or pro-biotics within 3 months pre-intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Intervention group
Participants with hypetriglyceridemia will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
|
1 soft gel capsule of Mastiha oil every day for 3 months
|
|
Active Comparator: Control group
Participants with hypetriglyceridemia will be subjected to nutritional counsel for a total of 3 months.
|
nutritional counsel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood triglycerides
Time Frame: 3 months
|
Levels will be evaluated pre and prost intervention in both control and intervention groups
|
3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MastihaOil-HT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertriglyceridemia
-
Ionis Pharmaceuticals, Inc.RecruitingHypertriglyceridemia | Severe HypertriglyceridemiaUnited States
-
Eli Lilly and CompanyRecruitingSevere HypertriglyceridemiaUnited States, China, Japan, Canada
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Australia, Canada, Germany, Hungary, Netherlands, New Zealand, Poland
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
-
AstraZenecaRadiant ResearchCompletedSevere HypertriglyceridemiaUnited States
-
Trygg Pharma, Inc.UnknownSevere HypertriglyceridemiaUnited States
-
SUNHO(China)BioPharmaceutical CO., Ltd.Not yet recruitingHealthy Subjects | Hyperlipidemia, HypertriglyceridemiaChina
-
Ionis Pharmaceuticals, Inc.CompletedSevere HypertriglyceridemiaFinland, United States, France, Israel, Netherlands, Denmark, Spain, Australia, United Kingdom, Germany, Italy, Canada, Czechia, Hungary, Bulgaria, New Zealand, Sweden, South Africa, Poland, Norway, Portugal, Slovakia, Turkey (Türkiye)
-
Arrowhead PharmaceuticalsActive, not recruitingSevere HypertriglyceridemiaUnited States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Hungary, Italy, Poland, Romania, Slovakia, Spain, United Kingdom
-
89bio, Inc.Active, not recruitingSevere HypertriglyceridemiaUnited States, Puerto Rico, Hungary, Poland, Argentina, Austria, Belgium, Bulgaria, Canada, Chile, Czechia, France, Georgia, Germany, India, Italy, Latvia, Mexico, Spain, United Kingdom